NCT05643508

A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia

A Randomized, Double-blind, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Hypertension and Dyslipidemia

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.

Detailed description

The study design is a randomized, double-blind, multicenter clinical trial. The patients were randomly assigned to each group. Primary endpoint was the change of MSSBP based on baseline between Treatment arm and control 1 arm and the change of LDL-C based on baseline between arm and control 2 arm.

Conditions

• Hypertension
• Hyperlipidemias

Interventions

Type	Name	Description
DRUG	(D) DWC202206	Drug of DWC202206 A mg
DRUG	(D) DWC202207	Drug of DWC202207 B/C mg
DRUG	(P) DWC202206	Placebo of DWC202206 A mg
DRUG	(P) DWC202207	Placebo of DWC202207 B/C mg

Timeline

• Start date: 2022-12-01
• Primary completion: 2024-03-01
• Completion: 2024-03-01
• First posted: 2022-12-08
• Last updated: 2022-12-12